The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | MRD as a predictor of risk in myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, provides an overview of using minimal residual disease (MRD) to guide myeloma treatment. Despite initial concerns using MRD-guided therapy, MRD is a strong predictor of risk and outcomes, where MRD status can determine duration of therapy. Dr Costa additionally highlights potential clinical trials that utilizes the MRD status of patients to escalate or deescalate therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
